Program
pertuzumab
Also written as “Pertuzumab”, “Pertuzumab IV” and “Perjeta”.
Its studies are mostly in Breast Neoplasms · Ovarian Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Prostatic Neoplasms, led by 6 companies.
Drug pagePertuzumab: every studyMany companies study it; this page follows only the 46 they lead. All 156 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 411 open or running | phase 4since May 13, 2015 | Nov 15, 2001 | Mar 28, 2027phase 3 · NCT02320435 |
| Cinnagenits history only | 10 open or running | phase 3since Jun 22, 2021 | Jun 22, 2021 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since Nov 25, 2022 | Nov 25, 2022 | none ahead |
| Mabscaleits history only | 11 open or running | phase 1since Apr 11, 2023 | Apr 11, 2023 | none ahead |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Aug 27, 2014 | Aug 27, 2014 | none ahead |
| Zydus Lifesciencesits history only | 10 open or running | phase 3since Feb 26, 2022 | Feb 26, 2022 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo and Roche Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Hoffmann-La Roche only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Nov 15, 2001.
- Dec 16, 2014Phase 3 study in Solid TumorsNCT02320435 · 154 enrolled · Brazil, China, Costa Rica and more
- May 13, 2015Phase 4 study in Breast NeoplasmsNCT02445586 · 52 enrolled · India
- Jun 5, 20152 phase 2 studiesNCT02480010, NCT02491892
- Jul 2, 20153 phase 1 studiesNCT02490475, NCT02494596, NCT02507375
- Aug 10, 2015Phase 2 study in Breast NeoplasmsNCT02536339 · 40 enrolled · United States
- Oct 23, 2015Phase 3 study in Breast NeoplasmsNCT02586025 · 329 enrolled · China, Korea, Republic of, Taiwan and more
- Mar 29, 2016Phase 1 study in Breast NeoplasmsNCT02738970 · 88 enrolled · New Zealand
- Sep 7, 2016Phase 3 study in Breast NeoplasmsNCT02896855 · 243 enrolled · China
- Apr 4, 2018Phase 3 study in Breast NeoplasmsNCT03493854 · 500 enrolled · United States, Argentina, Belgium and more
- Apr 5, 2018Phase 2 study in Neoplasms, Unknown PrimaryNCT03498521 · 529 enrolled · Australia, Austria, Brazil and more
- Sep 12, 2018Phase 2 study in HER2-Positive Early Breast CancerNCT03674112 · 160 enrolled · United States, Argentina, Brazil and more
- Jul 17, 2019Phase 3 study in HER2-positive Early Breast CancerNCT04024462 · 200 enrolled · China
- Jan 25, 2022Named pertuzumabINNProposed as its International Nonproprietary Name in WHO's List 126
- Jun 8, 2022Phase 3 study in Breast NeoplasmsNCT05415215 · 346 enrolled · Argentina, Bosnia and Herzegovina, Brazil and more
- Nov 6, 2026Primary completion moved from 2026-12-31 to 2027-03-28Date moved laterphase 3 · +3 months · NCT02320435
Ahead
- Mar 28, 2027Primary completion: phase 3 study in Solid TumorsNCT02320435
TargetBeta
“A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor”NCIt, by rule
“Receptor protein-tyrosine kinase erbB-2 inhibitor”ChEMBL 37, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 41 Hoffmann-La Roche leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05415215Breast Neoplasms · Argentina, Bosnia and Herzegovina, Brazil and more | 3 | Completed | Nov 20, 2024 | 346 |
| NCT04024462HER2-positive Early Breast Cancer · China | 3 | Completed | Dec 13, 2021 | 200 |
| NCT03674112HER2-Positive Early Breast Cancer · United States, Argentina, Brazil and more | 2 | Completed | Feb 24, 2020 | 160 |
| NCT03498521Neoplasms, Unknown Primary · Australia, Austria, Brazil and more | 2 | Completed | Feb 14, 2023 | 529 |
| NCT03493854Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Completed | Jul 4, 2019 | 500 |
| NCT02896855Breast Neoplasms · China | 3 | Completed | Jun 27, 2018 | 243 |
| NCT02738970Breast Neoplasms · New Zealand | 1 | Completed | May 31, 2018 | 88 |
| NCT02586025Breast Neoplasms · China, Korea, Republic of, Taiwan and more | 3 | Completed | Oct 23, 2017 | 329 |
| NCT02536339Breast Neoplasms · United States | 2 | Completed | May 1, 2019 | 40 |
| NCT02507375Carcinoma, Non-Small-Cell Lung · Belgium, Spain, United Kingdom | 1 | Completed | Dec 2008 | 17 |
| NCT02494596Solid Tumor · Spain, United Kingdom | 1 | Completed | Sep 2005 | 19 |
| NCT02490475Solid Tumor · Netherlands, United Kingdom | 1 | Completed | Apr 2006 | 19 |
| NCT02491892Breast Neoplasms · Australia, Belgium, Finland and more | 2 | Completed | Apr 2005 | 79 |
| NCT02480010Prostatic Neoplasms · France, Germany, Italy and more | 2 | Terminated | Sep 2005 | 68 |
| NCT02445586Breast Neoplasms · India | 4 | Completed | Sep 26, 2018 | 52 |
| NCT02320435Solid Tumors · Brazil, China, Costa Rica and more | 3 | Active, not recruiting | Mar 28, 2027 | 154 |
| NCT02291289Colorectal Neoplasms · Argentina, Belgium, Bosnia and Herzegovina and more | 2 | Completed | May 31, 2019 | 1,044 |
| NCT02132949Breast Neoplasms · United States, Canada, Denmark and more | 2 | Completed | Mar 3, 2016 | 401 |
| NCT02091141Neoplasms · United States | 2 | Completed | May 24, 2023 | 673 |
| NCT02004093Ovarian Neoplasms · Belgium, Canada, Hungary and more | 2 | Completed | Sep 2008 | 149 |
| NCT01774786Stomach Neoplasms · United States, Australia, Austria and more | 3 | Completed | Dec 9, 2016 | 780 |
| NCT01684878Ovarian Neoplasms · Austria, Belgium, Denmark and more | 3 | Completed | Jan 30, 2015 | 208 |
| NCT01674062Breast Neoplasms · Canada, France, Italy and more | 2 | Completed | Feb 2008 | 95 |
| NCT01572038Breast Neoplasms · Algeria, Argentina, Australia and more | 3 | Completed | Sep 20, 2019 | 1,436 |
| NCT01565083Breast Neoplasms · United States, Brazil, Denmark and more | 2 | Completed | Oct 2015 | 213 |
| NCT01491737Breast Neoplasms · United States, Brazil, France and more | 2 | Completed | Mar 17, 2016 | 258 |
| NCT01461057Stomach Neoplasms · Belgium, Czechia, France and more | 2 | Completed | Mar 1, 2015 | 30 |
| NCT01358877Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Dec 19, 2016 | 4,804 |
| NCT01120184Breast Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Sep 30, 2014 | 1,095 |
| NCT01026142Breast Neoplasms · Argentina, Austria, Belgium and more | 3 | Completed | May 29, 2015 | 452 |
| NCT00976989Breast Neoplasms · Bahamas, Bosnia and Herzegovina, Brazil and more | 2 | Completed | Jun 2011 | 225 |
| NCT00875979Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Aug 2011 | 67 |
| NCT00855894Carcinoma, Non-Small-Cell Lung · United States, Australia | 2 | Completed | Mar 2012 | 41 |
| NCT00567190Breast Neoplasms · United States, Argentina, Brazil and more | 3 | Completed | May 13, 2011 | 808 |
| NCT00545688Breast Neoplasms · Australia, Austria, Brazil and more | 2 | Completed | Sep 22, 2014 | 417 |
| NCT00096993Ovarian Neoplasms · United States | 2 | Completed | Sep 2007 | 131 |
| NCT00096941Solid Cancers | 2 | Completed | Oct 2007 | 3 |
| NCT00063154Carcinoma, Non-Small-Cell Lung · United States | 2 | Completed | Apr 2005 | 51 |
| NCT00058552Ovarian Neoplasms | 2 | Completed | Jul 2004 | 129 |
| NCT00058539Prostatic Neoplasms | 2 | Completed | Oct 2004 | 42 |
| NCT00027027Neoplasms · United States | 1 | Completed | Aug 2003 | 21 |
How it is read
Names in the registry
- “Pertuzumab”, 36 entries
- “Pertuzumab IV”, 4 entries
- “Perjeta”, 3 entries
- “pertuzumab”, 2 entries
- “RhuMab 2C4”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 34 studies
- Ovarian Neoplasms, 4 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Stomach Neoplasms, 2 studies
- Prostatic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.